In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids

Benjamin Besse; Jordi Remon

doi:10.1016/j.jtho.2019.07.029

In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids

Benjamin Besse, Jordi Remon

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e260-e261
Journal	Journal of Thoracic Oncology
Volume	14
Issue number	11
DOIs	https://doi.org/10.1016/j.jtho.2019.07.029
Publication status	Published - 1 Nov 2019

Access to Document

10.1016/j.jtho.2019.07.029

Cite this

@article{2ba6a188befe45e1a5fcbf56022e4055,

title = "In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids",

author = "Benjamin Besse and Jordi Remon",

note = "Funding Information: Disclosure: Dr. Remon reports personal fees from MSD and Boehringer Ingelheim for serving on advisory boards, speaker fees from Pfizer, personal fees and nonfinancial support from OSE Immunotherapeutics, personal fees and reimbursement for travel expenses from BMS and AstraZeneca, and reimbursement for travel expenses from Roche outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Blueprint Medicines, BMS, Celgene, Cristal Therapeutics, Eli Lilly, GSK, Ignyta, Ipsen, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunopharmaceutics, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work.",

year = "2019",

month = nov,

day = "1",

doi = "10.1016/j.jtho.2019.07.029",

language = "English",

volume = "14",

pages = "e260--e261",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "11",

}

TY - JOUR

T1 - In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy

T2 - Forcing on Organ-Specific irAEs and the Critical Role of Steroids

AU - Besse, Benjamin

AU - Remon, Jordi

N1 - Funding Information: Disclosure: Dr. Remon reports personal fees from MSD and Boehringer Ingelheim for serving on advisory boards, speaker fees from Pfizer, personal fees and nonfinancial support from OSE Immunotherapeutics, personal fees and reimbursement for travel expenses from BMS and AstraZeneca, and reimbursement for travel expenses from Roche outside the submitted work. Dr. Besse reports grants from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Blueprint Medicines, BMS, Celgene, Cristal Therapeutics, Eli Lilly, GSK, Ignyta, Ipsen, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunopharmaceutics, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work.

PY - 2019/11/1

Y1 - 2019/11/1

UR - http://www.scopus.com/inward/record.url?scp=85073740992&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.07.029

DO - 10.1016/j.jtho.2019.07.029

M3 - Letter

C2 - 31668327

AN - SCOPUS:85073740992

SN - 1556-0864

VL - 14

SP - e260-e261

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 11

ER -

In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids

Access to Document

Other files and links

Cite this